View ValuationSenzime 将来の成長Future 基準チェック /26Senzime収益と収益がそれぞれ年間76.8%と40.3%増加すると予測されています。主要情報76.8%収益成長率n/aEPS成長率Medical Equipment 収益成長16.2%収益成長率40.3%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日23 Apr 2026今後の成長に関する最新情報お知らせ • Feb 17+ 1 more updateSenzime AB (Publ) Provides Revenue Guidance for 2025Senzime AB (publ) provided revenue guidance for 2025. For the period, the company expects guidance of SEK 110 million to SEK 140 million.すべての更新を表示Recent updatesお知らせ • Jun 05Senzime Launches Tetraanalytics Data Analytics Platform and Showcases Expanded Tetragraph Capabilities At Euroanaesthesia 2026Senzime AB announced the launch of TetraAnalytics, a new data analytics platform designed to expand the value of the TetraGraph system. TetraAnalytics generates advanced clinical and operational insights, helping hospitals align with clinical guidelines, increase utilization and further leverage the benefits of quantitative neuromuscular monitoring. TetraAnalytics complements the TetraGraph ecosystem by providing hospitals and anesthesia departments with a new cloud-based platform to automate data analysis, track alignment with protocols and guidelines, support best-practice monitoring conditions using the proprietary Train-of-Four Quality Indicator (TQi), and drive continuous improvement across perioperative care. The platform also enables advanced data visualization and remote analytics capabilities, helping institutions strengthen implementation of quantitative neuromuscular monitoring and accelerate adoption of evidence-based care. Senzime will showcase TetraAnalytics, the next-generation TetraGraph system and the recently launched new TetraSens EMG sensor in booth 3.36 at Euroanaesthesia 2026, the annual congress of the European Society of Anaesthesiology and Intensive Care, taking place June 6–8, 2026, in Rotterdam. During Euroanaesthesia 2026, Senzime is also sponsoring a lunch symposium titled “From Acceleration to Precision: How New Technologies and Guidelines Are Advancing Neuromuscular Monitoring” on Saturday, June 6, from 12:00–13:00 in Room Rotterdam B. The session will be moderated by Sorin J. Brull, MD, FCARCSI (Hon), and feature Oscar Diaz, MD, PhD; Aaron Persinger, MD; Nicola Disma, MD, PhD; and Debra Faulk, MD. The discussion will explore how new comparative data, real-world clinical experience, and evolving guidelines are shaping the next standard of neuromuscular care in adults and children. TetraAnalytics is Senzime’s cloud-based data analytics platform for neuromuscular monitoring. The platform is designed to help healthcare institutions securely review TetraGraph case data, uncover clinical and operational insights, support best-practice monitoring conditions using the proprietary Train-of-Four Quality Indicator (TQi), and evaluate compliance with institutional protocols and clinical guidelines. The platform supports data-driven improvement in neuromuscular block management and expands the value of the TetraGraph ecosystem from real-time monitoring to longitudinal clinical insight.お知らせ • Feb 02+ 1 more updateSenzime AB (publ) to Report Q2, 2026 Results on Jul 16, 2026Senzime AB (publ) announced that they will report Q2, 2026 results on Jul 16, 2026お知らせ • Nov 04Senzime AB (publ), Annual General Meeting, May 19, 2026Senzime AB (publ), Annual General Meeting, May 19, 2026.お知らせ • Sep 30+ 2 more updatesSenzime AB (publ) to Report Fiscal Year 2025 Final Results on Apr 24, 2026Senzime AB (publ) announced that they will report fiscal year 2025 final results on Apr 24, 2026お知らせ • Jul 10Senzime AB (Publ.) Receives FDA and UKCA Approval to Launch Its Integrated HN-100 Nemomuscular Transmission Module in the US and UK MarketsSenzime AB (publ.) announced that its licensee, Fukuda Denshi, has received FDA and UKCA approvals to launch its integrated HN-100 neuromuscular transmission module in the US and UK markets. The HN-100 module, powered by Senzime's TetraGraph®? technology, is the first stand-alone electromyography (EMG)-based solution designed for plug-and-play integration with Fukuda Denshi's line of bedside patient monitors. Originally launched in Japan in 2024, the HN-100 module has quickly gained traction as a smart, efficient solution for enabling EMG-based Train-of-Four monitoring directly through Fukuda's Dynascope series of bedside monitors. Sold as an accessory, the HN- 100 module is used in combination with Senzime's portfolio of disposable EMG sensors. Fukuda Denshi Co. Ltd. has held a license agreement with Senzime since 2016. Under the agreement, Fukuda Denshi holds exclusive and certain non-exclusive rights to license and commercialize Senzime's Tetra Graph technology in Japan and selected international markets under its own brand. Senzime generates revenue from Fukuda through manufacturing of select products and variable royalty compensation based on actual sales.お知らせ • Jun 04Senzime AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 110.4 million.Senzime AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 110.4 million. Security Name: Shares Security Type: Common Stock Securities Offered: 23,300,000 Price\Range: SEK 4.6 Security Name: Shares Security Type: Common Stock Securities Offered: 700,000 Price\Range: SEK 4.6 Transaction Features: Subsequent Direct Listingお知らせ • May 27Senzime AB (publ.) Announces Upcoming European Pediatric Guidelines of Neuromuscular MonitoringSenzime AB (publ.) announced pre-announcement of the first pediatric guidelines of quantitative neuromuscular monitoring during anesthesia. The guideline announcement was done at the Euroanaesthesia 2025 (ESAIC) congress in Lisbon with final publication and announcement expected later in 2025, representing a significant update to pediatric anesthesia practice. Each year, approximately 10-12 million pediatric major surgeries are performed worldwide with neuromuscular blocking drugs, with around 3 million in the US alone. Research has shown that without proper monitoring, over 40% of pediatric patients experience residual neuromuscular block (rNMB) postoperatively, leading to respiratory complications, airway obstruction, and delayed recovery. Despite the well-documented risks of rNMB, pediatric anesthesia has historically relied on qualitative neuromuscular monitoring or no monitoring at all, due to the lack of specialized pediatric solutions. The pre-announced guidelines call for a recommendation of quantitative neurOMuscular monitoring, ensuring that paralytic and reversal drugs are properly dosed, and rNMB is avoided. Senzime's TetraGraph®? system is the only neuromuscular monitor on the market with a separate and specific FDA-cleared electromyography (EMG) sensor for use on patients from one month old. Unlike legacy neuromuscular monitors, TetraGraph monitors use EMG to accurately analyze the direct effects of paralytic drugs and does not require free-moving muscles, making it ideal for pediatric and tucked-arm cases such as robotic surgical procedures.お知らせ • Apr 24Senzime AB (publ) to Report Q3, 2025 Results on Nov 06, 2025Senzime AB (publ) announced that they will report Q3, 2025 results on Nov 06, 2025お知らせ • Apr 14Senzime AB (publ), Annual General Meeting, May 19, 2025Senzime AB (publ), Annual General Meeting, May 19, 2025, at 16:00 W. Europe Standard Time. Location: at the companys premises, on verkstadsgatan 8, house 1, uppsala Swedenお知らせ • Feb 17+ 1 more updateSenzime AB (Publ) Provides Revenue Guidance for 2025Senzime AB (publ) provided revenue guidance for 2025. For the period, the company expects guidance of SEK 110 million to SEK 140 million.お知らせ • Jan 07Senzime AB (publ) Secures Multiple New Hospital Contracts for Its Next-Generation TetraGraph SystemSenzime AB (publ) announced multiple hospital contract wins for its new TetraGraph system, and that first customer deliveries of the system has commenced as planned. The next-generation TetraGraph system was launched at the ANESTHESIOLOGY congress in US in late October 2024. Following the launch, the new TetraGraph has been used at multiple leading US, German and Swiss hospitals. New contracts include next-generation TetraGraph orders from a major US university hospital system located in the Southeast of initial 62 systems, orders from a leading US mountain region-based university hospital for initial 25 systems, and expansion orders of monitors from the highest ranked US hospital system. In addition, Senzime has secured a second important win in Switzerland where all operating rooms of a public healthcare hospital system will be equipped with next-generation monitors. Contracted new orders exceed 110 monitors in total. The TetraGraph system is used by anesthesiologists at over 500 leading hospitals across the globe to help improve patient safety during and after surgery. TetraGraph monitors the electrical activity of the patient’s muscle function to help define the right individual dose of neuromuscular blocking drugs and their antagonists, as well as indicate when it is safe to allow patients to breathe on their own again after surgery. The next-generation TetraGraph is the first EMG-based neuromuscular monitor designed with proprietary guideline-compliant features to help accelerate the adoption to the clinical guidelines published in 2023 by the leading anesthesiology societies ASA (American Society of Anesthesiologists) and ESAIC (European Society of Anaesthesiology and Intensive Care).お知らせ • Nov 07+ 2 more updatesSenzime AB (publ) to Report Q1, 2025 Results on May 07, 2025Senzime AB (publ) announced that they will report Q1, 2025 results on May 07, 2025お知らせ • Oct 29Senzime Successfully Unveils Next-Generation TetraGraph Quantitative Train-Of-Four Monitor at ANESTHESI Technology 2024Senzime announced the successful unveiling of its next-generation TetraGraph system at the ANESTHESIOLOGY 2024 congress. Developed in close collaboration with anesthesiologists from around the world, this innovative device is poised to redefine quantitative train-of-four (TOF) monitoring with precision-driven technology and advanced algorithms. The next-generation TetraGraph was designed in response to the growing need for more precise, reliable, and automated perioperative monitoring, aimed at reducing complications from residual neuromuscular block (rNMB), which continues to affect a significant percentage of surgical patients. Equipped with TetraGraph Adaptive Intelligence, the system delivers real-time data, helping clinicians enhance patient safety by making better-informed decisions throughout the perioperative journey. The new TetraGraph also features a sustainable design with upgradable software, providing long-term reliability and future-proofing for evolving healthcare needs. Senzime is excited to announce that U.S. shipments will begin in fourth quarter 2024, with orders being processed on a first-come, first-serve basis. To learn more about the next-generation TetraGraph and its gamechanging capabilities, join the launch webinar on October 30, 2024, from 9:00 - 9:30 am CST.お知らせ • Oct 15Senzime to Launch Next-Generation Tetragraph System At Anesthesiology 2024 ConferenceSenzime announced the launch of its next-generation TetraGraph system at the annual ANESTHESIOLOGY 2024 conference commencing on October 18th, 2024, in Philadelphia, USA. The next-generation TetraGraph is designed to redefine the standards of quantitative train-of-four (TOF) monitoring and enhance patient safety. New features include: Neuromuscular monitoring just got a lot smarter. Introducing TetraGraph Adaptive Intelligence including a suite of smart algorithms enabling true precision-based monitoring and automated workflows throughout the perioperative journey. Revolutionary, new user interface. The TetraGraph Level-of-Block Gauge makes complex neuromuscular monitoring understandable to help accelerate alignment to new clinical guidelines. Advancing Beyond the Twitch. Powered by decades of science and a 6th generation EMG-algorithm with 4x higher resolution for unprecedented clinical accuracy, real-time data trends, and external interoperability. The next-generation TetraGraph system has been developed in close partnership with industry leaders, including leading US anesthesiologists. It is first in its space to be engineered using sustainable materials and manufactured in an environmentally friendly ISO14001 certified process. The high-resolution, future-proofed platform has capabilities to integrate additional software features and connects to the industry's most comprehensive portfolio of EMG-based sensors. The new next-generation TetraGraph will be marketed alongside the classic, first-generation TetraGraph that was introduced to the market in 2019 and now used in thousands of operating rooms across the globe.お知らせ • Jun 25Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph SystemSenzime AB (publ.) announced that the European Patent Office (EPO) has issued a new patent protecting unique capabilities of the Senzime TetraGraph system. Every year, approximately 100 million patients receive neuromuscular blocking drugs as part of anesthesia to facilitate endotracheal intubation and optimize surgical conditions. Recent guidelines recommend that these patients shall be monitored by a quantitative neuromuscular monitor to ensure patient safety, and it is crucial that such monitors are not affected by periodic noise disturbances in the operating room. The new European patent protects the TetraGraph system's unique noise-cancelling features. The integrated technology optimizes electromyography (EMG)-based signal quality by mitigating disturbances from external, periodic noises that may be present in an operating room. This improvement ensures accurate indications, personalized drug dosing, precise timing of extubation, and more. The TetraGraph system, a quantitative neuromuscular monitoring solution, is used by anesthesiologists at hundreds of leading hospitals worldwide. Its proprietary technology enables anesthesiologists to accurately determine the appropriate dose of neuromuscular blocking drugs and their antagonists and to help identify when patients have safely recovered after surgery. Senzime's comprehensive patent portfolio now includes more than 90 patents related to its products and technologies, reinforcing its commitment to innovation and patient safety.お知らせ • Nov 29Senzime AB (publ) Announces Board ChangesSenzime AB (publ) announced that at the EGM was held on 28 November 2023, the company approved the at the general meeting, the leaving board directors Jenny Freeman and Laura Piccinini were thanked for their time in the board and their active contributions to the development of Senzime. Lars Axelson and Per Wold Olsen. Per Wold Olsen was elected chairman of the board of directors.お知らせ • Nov 09Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia OpenSenzime announced a new clinical study with the TetraGraph system published in the British Journal of Anesthesia Open (BJA Open). The study is the first of its kind and validates TetraGraph system waveforms using an AI-based neural network with an accuracy of more than 99%. The new study was performed by a research team at the University of Miami using clinical data from Mayo Clinic and the University of Debrecen to develop and validate an artificial intelligence (AI)-based convolutional neural network (CNN) that correctly identifies valid compound muscle action potentials (CMAPs) from the TetraGraph quantitative neuromuscular monitoring system. The study used Senzime's TetraGraph system to demonstrate the feasibility of using AI to separate valid cMAPs from artifact. The CNN algorithm showed an accuracy exceeding 99.5% in distinguishing the TetraGraph's valid CMAPs from artifact. The study Validation of a convolutional neural network that reliably identifies electromyographic compound motor action potentials following train-of-four stimulation: an algorithm development experimental study has been published in British Journal of Anesthesia Open. A related abstract was selected as one of the 12 Best Basic Science abstracts presented at the 2023 Annual Meeting of the American Society of Anesthesiologists in San Francisco, USA.お知らせ • Oct 27+ 4 more updatesSenzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024Senzime AB (publ) announced that they will report fiscal year 2023 results on Feb 15, 2024お知らせ • Oct 10Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive SkinSenzime launched TetraSensitive, the market's first disposable electromyography (EMG)-powered sensor intended for neuromuscular monitoring (NMT) of patients with sensitive skin. TetraSensitive, with a unique, patented design, targets a rapidly growing number of patients with delicate and fragile skin undergoing surgical procedures. More than half of all surgical procedures are performed on patients over 65 years of age. Due to ageing, the skin becomes more fragile because of a gradual loss of subcutaneous fat, causing skin to become more vulnerable to the damage that may be caused by conventional adhesives used in monitoring patches. Senzime's new TetraSensitive is the first EMG sensor designed specifically for neuromuscular monitoring of patients with sensitive and fragile skin. Its novel design combines advanced technology using an ultrasoft stretchable material and a flexible silver print to create a natural contact with the skin and eliminate discomfort. TetraSensitive is developed to provide superior adhesion without sharp edges, and the smart sizing design makes it ideal for different patient sizes. The TetraSensitive is protected by valid EU and US patent laws. The new disposable TetraSensitive EMG sensor is used with the portable TetraGraph quantitative neuromuscular monitor. The new product will be showcased at the American Anesthesiology 2023, Society of Anesthesiologists annual meeting, in San Francisco, October 13-17, and will be available for customer deliveries in US and European markets from early November 2023.お知らせ • Jul 04Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable SensorSenzime AB (publ) announced a new study validating the feasibility of TetraSens pediatric disposable sensor. The study was performed at the Nationwide Children's Hospital, Columbus, US, and evaluated Senzime's TetraGraph using the TetraSens Pediatric sensor. The study demonstrated that the TetraGraph system can be used in infants and children, even those who weigh less than 10 kilograms. Quantitative Train-of-Four (TOF) neuromuscular monitoring has seen limited use in infants and children, primarily due to lack of adequate technology and effective equipment. The recently published study Intraoperative electromyographic monitoring in children using a novel pediatric sensor included 51 patients who ranged in age from 0.2 to 7.9 years and in weight from 4.2 to 36.0 kilograms. The study concludes that neuromuscular monitoring can be performed intraoperatively in pediatric patients who are less than 8 years of age using a novel commercially available EMG-based monitor (TetraGraph) with a recently developed pediatric sensor (TetraSens Pediatric).お知らせ • Jun 06Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection AlgorithmSenzime AB (publ) announced this weekend’s scientific presentation at Euroanaesthesia 2023 in Glasgow, UK, validating the latest enhanced TetraGraph electromyographic (EMG) detection algorithm. The scientific poster presentation Prospective evaluation of an enhanced electromyographic (EMG) detection algorithm includes an evaluation of TetraGraph’s latest EMG algorithm as compared to the previous generation for sensitivity and detection accuracy. The new EMG algorithm improves detection of EMGs in 100% of cases, without introducing false-positive EMGs. Improvements in EMG detection help better plan intraoperative drug dosing and optimal antagonism, decreasing residual paralysis and facilitating patient safety.お知らせ • May 05Senzime AB (Publ) Appoints Philip Siberg as Chief Executive OfficerSenzime AB (publ) announced that the company's board of directors has decided to appoint Philip Siberg, currently chairman of the board, as the new CEO. Philip takes up his new role immediately and thus replaces Pia Renaudin who has been CEO since February 2019. Philip Siberg has been chairman of Senzime since 2016 when the company acquired Acacia Designs BV, which Philip was the CEO of. Acacia Designs pioneered the development of the TetraGraph system based on research from Mayo Clinic in the USA, and it's Senzime's main line of business. Philip has solid experience from various CEO and chairman roles within the Life Science industry and especially commercialization of innovations in the US healthcare market. By the appointment of Philip, the Board believes that Senzime has increased chances to succeed with the commercialization that has rapidly commenced in the US, and Philip brings in deep insights into Senzime's product offering, organization, and market. The board would like to express a big thank you to Pia Renaudin for her wholehearted efforts as CEO of Senzime - not least during the COVID-19 pandemic when Senzime managed to carry out a global launch and show sales growth despite extremely difficult market conditions. Pia has worked hard and has been a strong contributor to taking Senzime to the very exciting position the company is in including recently communicated rapid growth rate. Adam Dahlberg succeeds Philip Siberg as chairman of the board. Adam is a member of the Crafoord family and thus represents Senzime's largest owner and a more than 20-year commitment to the company.お知らせ • Feb 10Senzime Receives Approval for Its Pediatric Sensor in JapanThe TetraSens® Pediatric sensor has received regulatory approval in Japan, further supporting the roll out of Senzime's innovative patient monitoring systemsUppsala, February 9, 2023. Senzime AB (publ) announced that the TetraGraph® system and the TetraSens Pediatric sensor have been approved for use in Japan. Following this approval, Fukuda Denshi, which is Senzime's licensing partner in Japan and a leading company within patient monitoring in Japan, has made its first order for TetraSens Pediatric. TetraGraph together with the flexible TetraSens Pediatric sensor enables accurate monitoring of infants and young children who are receiving muscle paralyzing drugs as part of anesthesia. Fukuda Denshi has since 2016 exclusive right to license and commercialize Senzime's TetraGraphsystem in the Japanese market. Along with previous approvals of Senzime's quantitative neuromuscular monitoring system, the approval of TetraSens Pediatric makes the entire TetraGraph offering available for use in Japan.お知らせ • Feb 01+ 1 more updateSenzime AB (publ) to Report Q3, 2023 Results on Oct 26, 2023Senzime AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023お知らせ • Jan 24Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023Senzime AB (publ) announced that they will report fiscal year 2022 results on Feb 01, 2023お知らせ • Dec 25Senzime AB (publ) Gets US Patent for OnZurf ProbeSenzime AB (publ) announced that the company's Patent application has been allowed for issuance as a patent for OnZurf Probe in the US. OnZurf is a microdialysis probe designed to monitor gastro-intestinal organs such as esophagus, stomach and liver. The OnZurf Probe was acquired by Senzime in 2016 and is based on an innovation by Dr. Pernilla Abrahamsson and clinical research at Umeå University. The development, including CE approval of OnZurf, was completed by Senzime in 2017. The probe is designed to enable continuous sampling from gastro-intestinal organs such as esophagus, stomach and liver. By monitoring the organ surface, it is possible to detect elevations in lactate and other metabolic markers as early indicators of ischemia and post-operative complications. As of November 2020, Senzime has out licensed the OnZurf probe for the European market transferring the legal manufacturing rights and all related product liabilities to the company Moss S.p. A based outside Milano, Italy. Senzime has retained the rights to commercialization of OnZurf on all markets outside of Europe, including the US.お知らせ • Nov 26Senzime Lands New Order from South Korea of SEK 1 MillionSenzime AB (publ) announced that they have received an additional order of TetraGraph systems and single use electrodes from their distributor in South Korea. The order value amounts to more than SEK 1 Million and delivery will take place during December. This is the fifth larger order placed by Senzimes distributor in South Korea since their market launch in August 2019. There are more than 3,000 hospitals in South Korea and more than 700 000 operations are performed annually where anesthesia and muscle relaxants are used. The company also expects that South Korea's state reimbursement system will include this type of disposable sensors in 2021.お知らせ • Nov 05Senzime AB (publ) Announces Nomination Committee for 2021 Annual General MeetingIn accordance with the resolution at the Annual General Meeting of Senzime AB (publ) on May 14, 2020, the three shareholders have on 1 September 2020 appointed a Nomination Committee for the 2021 Annual General Meeting. The three shareholders in terms of voting rights (considering owner groupings) as of September 1, 2020 are Adam Dahlberg and his family, AB Segulah and Handelsbanken Fonder. They have each appointed a member, as set out below, to form the Senzime Nomination Committee together with the Chairman of the Board. Adam Dahlberg (Chairman), Lennart Kalén, AB Segulah, Malin Björkmo, Handelsbanken Fonder, Philip Siberg, Chairman of the Board of Senzime AB (publ).お知らせ • Nov 03Senzime AB (Publ) Signs an Out-Licensing Agreement with the Moss S.P.ASenzime AB (publ) announced the signing of an out-licensing agreement with the Moss S.p.A. As a result of the agreement, Moss will assume 10-year manufacturing and sales rights for the OnZurf Probe on the European market. The license agreement is estimated to generate more than SEK 100 million in license royalties over the term. As a result of the out-licensing agreement, Senzime will transfer the legal manufacturing rights and all related product liabilities related to the OnZurf Probe to Moss, including any future development costs. Senzime will keep rights to commercialization of OnZurf on all markets outside of Europe. Moss will pay Senzime a fixed license royalty per unit sold on the European market over a period of 10 years. The fixed royalty level corresponds to a double-digit percentage of OnZurf Probe's estimated sales value. Forecasted royalty income to Senzime during the agreement period amounts to more than SEK 100 million and the first royalty payments are expected to occur in 2022.お知らせ • Oct 30Senzime AB (publ) Enters into an Exclusive Agreement with the Surgical CompanySenzime AB (publ) announced that the company has entered into an exclusive agreement with The Surgical Company (formerly Sebac) for the French market, and the first order to a university hospital in France is ready to be delivered. Market entry is driven by the new clinical guidelines in France supporting the use of Senzime’s products in surgery.お知らせ • Oct 19Senzime AB (Publ) Announces Management ChangesSenzime announced that Eva Walde is appointed new acting Board Member to be elected a at the next shareholders meeting. Eva has 20 years of experience in leading roles in companies such as Johnson & Johnson, Pfizer and Thermo Fisher. Eva is currently a Board member of Sedana Medical AB (publ.). The appointment of a new Board member has taken place through an external recruitment process on behalf of the Nomination Committee of Senzime, consisting of Philip Siberg, Adam Dahlberg, Lennart Kalén and Sorin J. Brull.お知らせ • Oct 04Senzime AB (publ) Receives Order from SwitzerlandSenzime AB (publ) announced that the company has received another order from its distributor Leuag in Switzerland. The order of TetraGraph systems with Philips Interface and disposable TetraSens sensors have been purchased to replace the hospitals current AMG systems. The order value amounts to approximately SEK 300,000 and delivery will take place during the current month. TetraGraph is a unique digital system that measures the presence and depth of neuromuscular blockade to enable the doctor to determine the correct drug dosage and assess when the patient is ready to breathe on their own without the risk of complications. In addition to Europe, Senzime has launched sales of TetraGraph in Japan, Australia, and the United States.業績と収益の成長予測OTCPK:SNZZ.F - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028331N/AN/AN/A112/31/2027232-26N/A2112/31/2026153-65N/A-4213/31/2026104-125-116-100N/A12/31/2025104-137-127-109N/A9/30/202590-121-124-103N/A6/30/202581-126-125-103N/A3/31/202570-125-131-109N/A12/31/202458-119-126-106N/A9/30/202455-131-129-113N/A6/30/202447-130-125-113N/A3/31/202441-131-119-110N/A12/31/202336-134-122-114N/A9/30/202329-138-121-114N/A6/30/202324-137-164-158N/A3/31/202319-143-159-153N/A12/31/202214-133-142-137N/A9/30/202213-114-133-128N/A6/30/202211-104-86-80N/A3/31/202212-86-84-80N/A12/31/202111-82-84-81N/A9/30/202111-74-78-76N/A6/30/202111-66-65-64N/A3/31/20218-56-50-50N/A12/31/20209-47-39-38N/A9/30/20209-41-31-30N/A6/30/20209-36-25-23N/A3/31/20209-32-25-22N/A12/31/20197-33N/A-27N/A9/30/20197-34N/A-25N/A6/30/20194-33N/A-28N/A3/31/20194-30N/A-25N/A12/31/20183-24N/A-17N/A9/30/20181-19N/A-16N/A6/30/20180-16N/A-13N/A3/31/20180-13N/A-11N/A12/31/20170-13N/A-12N/A9/30/20170-13N/A-13N/A6/30/20171-12N/A-14N/A3/31/20172-12N/A-13N/A12/31/20162-9N/A-10N/A9/30/20161-8N/A-8N/A6/30/20161-8N/A-7N/A3/31/20160-8N/A-6N/A12/31/20150-8N/A-6N/A9/30/20150-7N/A-6N/A6/30/20150-7N/A-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SNZZ.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: SNZZ.F今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: SNZZ.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: SNZZ.Fの収益 ( 40.3% ) US市場 ( 13% ) よりも速いペースで成長すると予測されています。高い収益成長: SNZZ.Fの収益 ( 40.3% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SNZZ.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 12:07終値2026/06/04 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Senzime AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Oscar StjerngrenDanske BankGustaf MeyerRedeye
お知らせ • Feb 17+ 1 more updateSenzime AB (Publ) Provides Revenue Guidance for 2025Senzime AB (publ) provided revenue guidance for 2025. For the period, the company expects guidance of SEK 110 million to SEK 140 million.
お知らせ • Jun 05Senzime Launches Tetraanalytics Data Analytics Platform and Showcases Expanded Tetragraph Capabilities At Euroanaesthesia 2026Senzime AB announced the launch of TetraAnalytics, a new data analytics platform designed to expand the value of the TetraGraph system. TetraAnalytics generates advanced clinical and operational insights, helping hospitals align with clinical guidelines, increase utilization and further leverage the benefits of quantitative neuromuscular monitoring. TetraAnalytics complements the TetraGraph ecosystem by providing hospitals and anesthesia departments with a new cloud-based platform to automate data analysis, track alignment with protocols and guidelines, support best-practice monitoring conditions using the proprietary Train-of-Four Quality Indicator (TQi), and drive continuous improvement across perioperative care. The platform also enables advanced data visualization and remote analytics capabilities, helping institutions strengthen implementation of quantitative neuromuscular monitoring and accelerate adoption of evidence-based care. Senzime will showcase TetraAnalytics, the next-generation TetraGraph system and the recently launched new TetraSens EMG sensor in booth 3.36 at Euroanaesthesia 2026, the annual congress of the European Society of Anaesthesiology and Intensive Care, taking place June 6–8, 2026, in Rotterdam. During Euroanaesthesia 2026, Senzime is also sponsoring a lunch symposium titled “From Acceleration to Precision: How New Technologies and Guidelines Are Advancing Neuromuscular Monitoring” on Saturday, June 6, from 12:00–13:00 in Room Rotterdam B. The session will be moderated by Sorin J. Brull, MD, FCARCSI (Hon), and feature Oscar Diaz, MD, PhD; Aaron Persinger, MD; Nicola Disma, MD, PhD; and Debra Faulk, MD. The discussion will explore how new comparative data, real-world clinical experience, and evolving guidelines are shaping the next standard of neuromuscular care in adults and children. TetraAnalytics is Senzime’s cloud-based data analytics platform for neuromuscular monitoring. The platform is designed to help healthcare institutions securely review TetraGraph case data, uncover clinical and operational insights, support best-practice monitoring conditions using the proprietary Train-of-Four Quality Indicator (TQi), and evaluate compliance with institutional protocols and clinical guidelines. The platform supports data-driven improvement in neuromuscular block management and expands the value of the TetraGraph ecosystem from real-time monitoring to longitudinal clinical insight.
お知らせ • Feb 02+ 1 more updateSenzime AB (publ) to Report Q2, 2026 Results on Jul 16, 2026Senzime AB (publ) announced that they will report Q2, 2026 results on Jul 16, 2026
お知らせ • Nov 04Senzime AB (publ), Annual General Meeting, May 19, 2026Senzime AB (publ), Annual General Meeting, May 19, 2026.
お知らせ • Sep 30+ 2 more updatesSenzime AB (publ) to Report Fiscal Year 2025 Final Results on Apr 24, 2026Senzime AB (publ) announced that they will report fiscal year 2025 final results on Apr 24, 2026
お知らせ • Jul 10Senzime AB (Publ.) Receives FDA and UKCA Approval to Launch Its Integrated HN-100 Nemomuscular Transmission Module in the US and UK MarketsSenzime AB (publ.) announced that its licensee, Fukuda Denshi, has received FDA and UKCA approvals to launch its integrated HN-100 neuromuscular transmission module in the US and UK markets. The HN-100 module, powered by Senzime's TetraGraph®? technology, is the first stand-alone electromyography (EMG)-based solution designed for plug-and-play integration with Fukuda Denshi's line of bedside patient monitors. Originally launched in Japan in 2024, the HN-100 module has quickly gained traction as a smart, efficient solution for enabling EMG-based Train-of-Four monitoring directly through Fukuda's Dynascope series of bedside monitors. Sold as an accessory, the HN- 100 module is used in combination with Senzime's portfolio of disposable EMG sensors. Fukuda Denshi Co. Ltd. has held a license agreement with Senzime since 2016. Under the agreement, Fukuda Denshi holds exclusive and certain non-exclusive rights to license and commercialize Senzime's Tetra Graph technology in Japan and selected international markets under its own brand. Senzime generates revenue from Fukuda through manufacturing of select products and variable royalty compensation based on actual sales.
お知らせ • Jun 04Senzime AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 110.4 million.Senzime AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 110.4 million. Security Name: Shares Security Type: Common Stock Securities Offered: 23,300,000 Price\Range: SEK 4.6 Security Name: Shares Security Type: Common Stock Securities Offered: 700,000 Price\Range: SEK 4.6 Transaction Features: Subsequent Direct Listing
お知らせ • May 27Senzime AB (publ.) Announces Upcoming European Pediatric Guidelines of Neuromuscular MonitoringSenzime AB (publ.) announced pre-announcement of the first pediatric guidelines of quantitative neuromuscular monitoring during anesthesia. The guideline announcement was done at the Euroanaesthesia 2025 (ESAIC) congress in Lisbon with final publication and announcement expected later in 2025, representing a significant update to pediatric anesthesia practice. Each year, approximately 10-12 million pediatric major surgeries are performed worldwide with neuromuscular blocking drugs, with around 3 million in the US alone. Research has shown that without proper monitoring, over 40% of pediatric patients experience residual neuromuscular block (rNMB) postoperatively, leading to respiratory complications, airway obstruction, and delayed recovery. Despite the well-documented risks of rNMB, pediatric anesthesia has historically relied on qualitative neuromuscular monitoring or no monitoring at all, due to the lack of specialized pediatric solutions. The pre-announced guidelines call for a recommendation of quantitative neurOMuscular monitoring, ensuring that paralytic and reversal drugs are properly dosed, and rNMB is avoided. Senzime's TetraGraph®? system is the only neuromuscular monitor on the market with a separate and specific FDA-cleared electromyography (EMG) sensor for use on patients from one month old. Unlike legacy neuromuscular monitors, TetraGraph monitors use EMG to accurately analyze the direct effects of paralytic drugs and does not require free-moving muscles, making it ideal for pediatric and tucked-arm cases such as robotic surgical procedures.
お知らせ • Apr 24Senzime AB (publ) to Report Q3, 2025 Results on Nov 06, 2025Senzime AB (publ) announced that they will report Q3, 2025 results on Nov 06, 2025
お知らせ • Apr 14Senzime AB (publ), Annual General Meeting, May 19, 2025Senzime AB (publ), Annual General Meeting, May 19, 2025, at 16:00 W. Europe Standard Time. Location: at the companys premises, on verkstadsgatan 8, house 1, uppsala Sweden
お知らせ • Feb 17+ 1 more updateSenzime AB (Publ) Provides Revenue Guidance for 2025Senzime AB (publ) provided revenue guidance for 2025. For the period, the company expects guidance of SEK 110 million to SEK 140 million.
お知らせ • Jan 07Senzime AB (publ) Secures Multiple New Hospital Contracts for Its Next-Generation TetraGraph SystemSenzime AB (publ) announced multiple hospital contract wins for its new TetraGraph system, and that first customer deliveries of the system has commenced as planned. The next-generation TetraGraph system was launched at the ANESTHESIOLOGY congress in US in late October 2024. Following the launch, the new TetraGraph has been used at multiple leading US, German and Swiss hospitals. New contracts include next-generation TetraGraph orders from a major US university hospital system located in the Southeast of initial 62 systems, orders from a leading US mountain region-based university hospital for initial 25 systems, and expansion orders of monitors from the highest ranked US hospital system. In addition, Senzime has secured a second important win in Switzerland where all operating rooms of a public healthcare hospital system will be equipped with next-generation monitors. Contracted new orders exceed 110 monitors in total. The TetraGraph system is used by anesthesiologists at over 500 leading hospitals across the globe to help improve patient safety during and after surgery. TetraGraph monitors the electrical activity of the patient’s muscle function to help define the right individual dose of neuromuscular blocking drugs and their antagonists, as well as indicate when it is safe to allow patients to breathe on their own again after surgery. The next-generation TetraGraph is the first EMG-based neuromuscular monitor designed with proprietary guideline-compliant features to help accelerate the adoption to the clinical guidelines published in 2023 by the leading anesthesiology societies ASA (American Society of Anesthesiologists) and ESAIC (European Society of Anaesthesiology and Intensive Care).
お知らせ • Nov 07+ 2 more updatesSenzime AB (publ) to Report Q1, 2025 Results on May 07, 2025Senzime AB (publ) announced that they will report Q1, 2025 results on May 07, 2025
お知らせ • Oct 29Senzime Successfully Unveils Next-Generation TetraGraph Quantitative Train-Of-Four Monitor at ANESTHESI Technology 2024Senzime announced the successful unveiling of its next-generation TetraGraph system at the ANESTHESIOLOGY 2024 congress. Developed in close collaboration with anesthesiologists from around the world, this innovative device is poised to redefine quantitative train-of-four (TOF) monitoring with precision-driven technology and advanced algorithms. The next-generation TetraGraph was designed in response to the growing need for more precise, reliable, and automated perioperative monitoring, aimed at reducing complications from residual neuromuscular block (rNMB), which continues to affect a significant percentage of surgical patients. Equipped with TetraGraph Adaptive Intelligence, the system delivers real-time data, helping clinicians enhance patient safety by making better-informed decisions throughout the perioperative journey. The new TetraGraph also features a sustainable design with upgradable software, providing long-term reliability and future-proofing for evolving healthcare needs. Senzime is excited to announce that U.S. shipments will begin in fourth quarter 2024, with orders being processed on a first-come, first-serve basis. To learn more about the next-generation TetraGraph and its gamechanging capabilities, join the launch webinar on October 30, 2024, from 9:00 - 9:30 am CST.
お知らせ • Oct 15Senzime to Launch Next-Generation Tetragraph System At Anesthesiology 2024 ConferenceSenzime announced the launch of its next-generation TetraGraph system at the annual ANESTHESIOLOGY 2024 conference commencing on October 18th, 2024, in Philadelphia, USA. The next-generation TetraGraph is designed to redefine the standards of quantitative train-of-four (TOF) monitoring and enhance patient safety. New features include: Neuromuscular monitoring just got a lot smarter. Introducing TetraGraph Adaptive Intelligence including a suite of smart algorithms enabling true precision-based monitoring and automated workflows throughout the perioperative journey. Revolutionary, new user interface. The TetraGraph Level-of-Block Gauge makes complex neuromuscular monitoring understandable to help accelerate alignment to new clinical guidelines. Advancing Beyond the Twitch. Powered by decades of science and a 6th generation EMG-algorithm with 4x higher resolution for unprecedented clinical accuracy, real-time data trends, and external interoperability. The next-generation TetraGraph system has been developed in close partnership with industry leaders, including leading US anesthesiologists. It is first in its space to be engineered using sustainable materials and manufactured in an environmentally friendly ISO14001 certified process. The high-resolution, future-proofed platform has capabilities to integrate additional software features and connects to the industry's most comprehensive portfolio of EMG-based sensors. The new next-generation TetraGraph will be marketed alongside the classic, first-generation TetraGraph that was introduced to the market in 2019 and now used in thousands of operating rooms across the globe.
お知らせ • Jun 25Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph SystemSenzime AB (publ.) announced that the European Patent Office (EPO) has issued a new patent protecting unique capabilities of the Senzime TetraGraph system. Every year, approximately 100 million patients receive neuromuscular blocking drugs as part of anesthesia to facilitate endotracheal intubation and optimize surgical conditions. Recent guidelines recommend that these patients shall be monitored by a quantitative neuromuscular monitor to ensure patient safety, and it is crucial that such monitors are not affected by periodic noise disturbances in the operating room. The new European patent protects the TetraGraph system's unique noise-cancelling features. The integrated technology optimizes electromyography (EMG)-based signal quality by mitigating disturbances from external, periodic noises that may be present in an operating room. This improvement ensures accurate indications, personalized drug dosing, precise timing of extubation, and more. The TetraGraph system, a quantitative neuromuscular monitoring solution, is used by anesthesiologists at hundreds of leading hospitals worldwide. Its proprietary technology enables anesthesiologists to accurately determine the appropriate dose of neuromuscular blocking drugs and their antagonists and to help identify when patients have safely recovered after surgery. Senzime's comprehensive patent portfolio now includes more than 90 patents related to its products and technologies, reinforcing its commitment to innovation and patient safety.
お知らせ • Nov 29Senzime AB (publ) Announces Board ChangesSenzime AB (publ) announced that at the EGM was held on 28 November 2023, the company approved the at the general meeting, the leaving board directors Jenny Freeman and Laura Piccinini were thanked for their time in the board and their active contributions to the development of Senzime. Lars Axelson and Per Wold Olsen. Per Wold Olsen was elected chairman of the board of directors.
お知らせ • Nov 09Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia OpenSenzime announced a new clinical study with the TetraGraph system published in the British Journal of Anesthesia Open (BJA Open). The study is the first of its kind and validates TetraGraph system waveforms using an AI-based neural network with an accuracy of more than 99%. The new study was performed by a research team at the University of Miami using clinical data from Mayo Clinic and the University of Debrecen to develop and validate an artificial intelligence (AI)-based convolutional neural network (CNN) that correctly identifies valid compound muscle action potentials (CMAPs) from the TetraGraph quantitative neuromuscular monitoring system. The study used Senzime's TetraGraph system to demonstrate the feasibility of using AI to separate valid cMAPs from artifact. The CNN algorithm showed an accuracy exceeding 99.5% in distinguishing the TetraGraph's valid CMAPs from artifact. The study Validation of a convolutional neural network that reliably identifies electromyographic compound motor action potentials following train-of-four stimulation: an algorithm development experimental study has been published in British Journal of Anesthesia Open. A related abstract was selected as one of the 12 Best Basic Science abstracts presented at the 2023 Annual Meeting of the American Society of Anesthesiologists in San Francisco, USA.
お知らせ • Oct 27+ 4 more updatesSenzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024Senzime AB (publ) announced that they will report fiscal year 2023 results on Feb 15, 2024
お知らせ • Oct 10Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive SkinSenzime launched TetraSensitive, the market's first disposable electromyography (EMG)-powered sensor intended for neuromuscular monitoring (NMT) of patients with sensitive skin. TetraSensitive, with a unique, patented design, targets a rapidly growing number of patients with delicate and fragile skin undergoing surgical procedures. More than half of all surgical procedures are performed on patients over 65 years of age. Due to ageing, the skin becomes more fragile because of a gradual loss of subcutaneous fat, causing skin to become more vulnerable to the damage that may be caused by conventional adhesives used in monitoring patches. Senzime's new TetraSensitive is the first EMG sensor designed specifically for neuromuscular monitoring of patients with sensitive and fragile skin. Its novel design combines advanced technology using an ultrasoft stretchable material and a flexible silver print to create a natural contact with the skin and eliminate discomfort. TetraSensitive is developed to provide superior adhesion without sharp edges, and the smart sizing design makes it ideal for different patient sizes. The TetraSensitive is protected by valid EU and US patent laws. The new disposable TetraSensitive EMG sensor is used with the portable TetraGraph quantitative neuromuscular monitor. The new product will be showcased at the American Anesthesiology 2023, Society of Anesthesiologists annual meeting, in San Francisco, October 13-17, and will be available for customer deliveries in US and European markets from early November 2023.
お知らせ • Jul 04Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable SensorSenzime AB (publ) announced a new study validating the feasibility of TetraSens pediatric disposable sensor. The study was performed at the Nationwide Children's Hospital, Columbus, US, and evaluated Senzime's TetraGraph using the TetraSens Pediatric sensor. The study demonstrated that the TetraGraph system can be used in infants and children, even those who weigh less than 10 kilograms. Quantitative Train-of-Four (TOF) neuromuscular monitoring has seen limited use in infants and children, primarily due to lack of adequate technology and effective equipment. The recently published study Intraoperative electromyographic monitoring in children using a novel pediatric sensor included 51 patients who ranged in age from 0.2 to 7.9 years and in weight from 4.2 to 36.0 kilograms. The study concludes that neuromuscular monitoring can be performed intraoperatively in pediatric patients who are less than 8 years of age using a novel commercially available EMG-based monitor (TetraGraph) with a recently developed pediatric sensor (TetraSens Pediatric).
お知らせ • Jun 06Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection AlgorithmSenzime AB (publ) announced this weekend’s scientific presentation at Euroanaesthesia 2023 in Glasgow, UK, validating the latest enhanced TetraGraph electromyographic (EMG) detection algorithm. The scientific poster presentation Prospective evaluation of an enhanced electromyographic (EMG) detection algorithm includes an evaluation of TetraGraph’s latest EMG algorithm as compared to the previous generation for sensitivity and detection accuracy. The new EMG algorithm improves detection of EMGs in 100% of cases, without introducing false-positive EMGs. Improvements in EMG detection help better plan intraoperative drug dosing and optimal antagonism, decreasing residual paralysis and facilitating patient safety.
お知らせ • May 05Senzime AB (Publ) Appoints Philip Siberg as Chief Executive OfficerSenzime AB (publ) announced that the company's board of directors has decided to appoint Philip Siberg, currently chairman of the board, as the new CEO. Philip takes up his new role immediately and thus replaces Pia Renaudin who has been CEO since February 2019. Philip Siberg has been chairman of Senzime since 2016 when the company acquired Acacia Designs BV, which Philip was the CEO of. Acacia Designs pioneered the development of the TetraGraph system based on research from Mayo Clinic in the USA, and it's Senzime's main line of business. Philip has solid experience from various CEO and chairman roles within the Life Science industry and especially commercialization of innovations in the US healthcare market. By the appointment of Philip, the Board believes that Senzime has increased chances to succeed with the commercialization that has rapidly commenced in the US, and Philip brings in deep insights into Senzime's product offering, organization, and market. The board would like to express a big thank you to Pia Renaudin for her wholehearted efforts as CEO of Senzime - not least during the COVID-19 pandemic when Senzime managed to carry out a global launch and show sales growth despite extremely difficult market conditions. Pia has worked hard and has been a strong contributor to taking Senzime to the very exciting position the company is in including recently communicated rapid growth rate. Adam Dahlberg succeeds Philip Siberg as chairman of the board. Adam is a member of the Crafoord family and thus represents Senzime's largest owner and a more than 20-year commitment to the company.
お知らせ • Feb 10Senzime Receives Approval for Its Pediatric Sensor in JapanThe TetraSens® Pediatric sensor has received regulatory approval in Japan, further supporting the roll out of Senzime's innovative patient monitoring systemsUppsala, February 9, 2023. Senzime AB (publ) announced that the TetraGraph® system and the TetraSens Pediatric sensor have been approved for use in Japan. Following this approval, Fukuda Denshi, which is Senzime's licensing partner in Japan and a leading company within patient monitoring in Japan, has made its first order for TetraSens Pediatric. TetraGraph together with the flexible TetraSens Pediatric sensor enables accurate monitoring of infants and young children who are receiving muscle paralyzing drugs as part of anesthesia. Fukuda Denshi has since 2016 exclusive right to license and commercialize Senzime's TetraGraphsystem in the Japanese market. Along with previous approvals of Senzime's quantitative neuromuscular monitoring system, the approval of TetraSens Pediatric makes the entire TetraGraph offering available for use in Japan.
お知らせ • Feb 01+ 1 more updateSenzime AB (publ) to Report Q3, 2023 Results on Oct 26, 2023Senzime AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023
お知らせ • Jan 24Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023Senzime AB (publ) announced that they will report fiscal year 2022 results on Feb 01, 2023
お知らせ • Dec 25Senzime AB (publ) Gets US Patent for OnZurf ProbeSenzime AB (publ) announced that the company's Patent application has been allowed for issuance as a patent for OnZurf Probe in the US. OnZurf is a microdialysis probe designed to monitor gastro-intestinal organs such as esophagus, stomach and liver. The OnZurf Probe was acquired by Senzime in 2016 and is based on an innovation by Dr. Pernilla Abrahamsson and clinical research at Umeå University. The development, including CE approval of OnZurf, was completed by Senzime in 2017. The probe is designed to enable continuous sampling from gastro-intestinal organs such as esophagus, stomach and liver. By monitoring the organ surface, it is possible to detect elevations in lactate and other metabolic markers as early indicators of ischemia and post-operative complications. As of November 2020, Senzime has out licensed the OnZurf probe for the European market transferring the legal manufacturing rights and all related product liabilities to the company Moss S.p. A based outside Milano, Italy. Senzime has retained the rights to commercialization of OnZurf on all markets outside of Europe, including the US.
お知らせ • Nov 26Senzime Lands New Order from South Korea of SEK 1 MillionSenzime AB (publ) announced that they have received an additional order of TetraGraph systems and single use electrodes from their distributor in South Korea. The order value amounts to more than SEK 1 Million and delivery will take place during December. This is the fifth larger order placed by Senzimes distributor in South Korea since their market launch in August 2019. There are more than 3,000 hospitals in South Korea and more than 700 000 operations are performed annually where anesthesia and muscle relaxants are used. The company also expects that South Korea's state reimbursement system will include this type of disposable sensors in 2021.
お知らせ • Nov 05Senzime AB (publ) Announces Nomination Committee for 2021 Annual General MeetingIn accordance with the resolution at the Annual General Meeting of Senzime AB (publ) on May 14, 2020, the three shareholders have on 1 September 2020 appointed a Nomination Committee for the 2021 Annual General Meeting. The three shareholders in terms of voting rights (considering owner groupings) as of September 1, 2020 are Adam Dahlberg and his family, AB Segulah and Handelsbanken Fonder. They have each appointed a member, as set out below, to form the Senzime Nomination Committee together with the Chairman of the Board. Adam Dahlberg (Chairman), Lennart Kalén, AB Segulah, Malin Björkmo, Handelsbanken Fonder, Philip Siberg, Chairman of the Board of Senzime AB (publ).
お知らせ • Nov 03Senzime AB (Publ) Signs an Out-Licensing Agreement with the Moss S.P.ASenzime AB (publ) announced the signing of an out-licensing agreement with the Moss S.p.A. As a result of the agreement, Moss will assume 10-year manufacturing and sales rights for the OnZurf Probe on the European market. The license agreement is estimated to generate more than SEK 100 million in license royalties over the term. As a result of the out-licensing agreement, Senzime will transfer the legal manufacturing rights and all related product liabilities related to the OnZurf Probe to Moss, including any future development costs. Senzime will keep rights to commercialization of OnZurf on all markets outside of Europe. Moss will pay Senzime a fixed license royalty per unit sold on the European market over a period of 10 years. The fixed royalty level corresponds to a double-digit percentage of OnZurf Probe's estimated sales value. Forecasted royalty income to Senzime during the agreement period amounts to more than SEK 100 million and the first royalty payments are expected to occur in 2022.
お知らせ • Oct 30Senzime AB (publ) Enters into an Exclusive Agreement with the Surgical CompanySenzime AB (publ) announced that the company has entered into an exclusive agreement with The Surgical Company (formerly Sebac) for the French market, and the first order to a university hospital in France is ready to be delivered. Market entry is driven by the new clinical guidelines in France supporting the use of Senzime’s products in surgery.
お知らせ • Oct 19Senzime AB (Publ) Announces Management ChangesSenzime announced that Eva Walde is appointed new acting Board Member to be elected a at the next shareholders meeting. Eva has 20 years of experience in leading roles in companies such as Johnson & Johnson, Pfizer and Thermo Fisher. Eva is currently a Board member of Sedana Medical AB (publ.). The appointment of a new Board member has taken place through an external recruitment process on behalf of the Nomination Committee of Senzime, consisting of Philip Siberg, Adam Dahlberg, Lennart Kalén and Sorin J. Brull.
お知らせ • Oct 04Senzime AB (publ) Receives Order from SwitzerlandSenzime AB (publ) announced that the company has received another order from its distributor Leuag in Switzerland. The order of TetraGraph systems with Philips Interface and disposable TetraSens sensors have been purchased to replace the hospitals current AMG systems. The order value amounts to approximately SEK 300,000 and delivery will take place during the current month. TetraGraph is a unique digital system that measures the presence and depth of neuromuscular blockade to enable the doctor to determine the correct drug dosage and assess when the patient is ready to breathe on their own without the risk of complications. In addition to Europe, Senzime has launched sales of TetraGraph in Japan, Australia, and the United States.